Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

4 - Evidence-based pharmacotherapy of major depressive disorder

Related content

Powered by UNSILO

References

Abraham G, Milev R, Stuart Lawson J (2006). T3 augmentation of SSRI resistant depression. Journal of Affective Disorders 91, 211–215.
Aiken CB (2007). Pramipexole in psychiatry: a systematic review of the literature. Journal of Clinical Psychiatry 68, 1230–1236.
Altshuler LL, Bauer M, Frye MA et al. (2001). Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry 158, 1617–1622.
Anderson IM (1998). SSRIs vs. tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7 (Suppl. 1), 11–17.
Anderson IM (2000). Selective serotonin reuptake inhibitors vs. tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19–36.
Angst J, Gamma A, Sellaro R et al. (2003). Recurrence of bipolar disorders and major depression. A life-long perspective. European Archives of Psychiatry and Clinical Neuroscience 253, 236–240.
Ballon JS, Feifel D (2006). A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 67, 554–566.
Barbosa L, Berk M, Vorster M (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64, 403–407.
Barbui C, Hotopf M, Freemantle N et al. (2003). Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) vs. tricyclic antidepressants (TCAs). Cochrane Database of Systematic Reviews 3, CD002791.
Carpenter LL, Yasmin S, Price LH (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 51, 183–188.
Cipriani A, Furukawa TA, Salanti G et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746–758.
Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. American Journal of Psychiatry 161, 414–415.
Corrigan MH, Denahan AQ, Wright CE et al. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11, 58–65.
Coryell W, Endicott J, Keller MB (1991). Predictors of relapse into major depressive disorder in a nonclinical population. American Journal of Psychiatry 148, 1353–1358.
Crossley NA, Bauer M (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 68, 935–940.
DeBattista C, Doghramji K, Menza MA et al. (2003). Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo- controlled study. Journal of Clinical Psychiatry 64, 1057–1064.
DeBattista C, Hawkins J (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23, 369–377.
DeBattista C, Lembke A, Solvason HB et al. (2004). A prospective trial of modafinil as an adjunctive treatment of major depression. Journal of Clinical Psychopharmacology 24, 87–90.
Elgamal S, MacQueen G (2008). Galantamine as an adjunctive treatment in major depression. Journal of Clinical Psychopharmacology 28, 357–359.
Fava M, Rush AJ, Wisniewski SR et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. American Journal of Psychiatry 163, 1161–1172.
Fava M, Thase ME, DeBattista C (2005). A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry 66, 85–93.
Fergusson D, Doucette S, Cranley Glass K, Shapiro S et al. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. British Medical Journal 330, 396.
Fochtman LJ, Gelenberg AJ (2005). Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn. American Psychiatric Association (http://www.psychiatryonline.com/pracGuide/ loadGuidelinePdf.aspx?file=MDD.watch).
Fournier JC, DeRubeis RJ, Hollon SD et al. (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association 303, 47–53.
Gartlehner G, Gaynes BN, Hansen RA et al. (2008). Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine 149, 734–750.
Geddes JR, Carney SM, Davies C et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661.
Geddes JR, Freemantle N, Mason J et al. (2002). Selective serotonin reuptake inhibitors (SSRIs) for depression. Cochrane Database of Systematic Reviews 2, CD00185.
Gibbons RD, Brown CH, Hur K et al. (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356–1363.
Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 62, 165–172.
Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163, 1898–1904.
Goodwin GM, Emsley R, Rembry S et al. (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 1128–1137.
Guaiana G, Barbui C, Hotopf M (2007). Amitriptyline for depression. Cochrane Database of Systematic Reviews 3, CD004186.
Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ (2007). Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of Clinical Psychiatry 68, 380–383.
Hansen R, Gaynes B, Thieda P et al. (2008). Meta-analysis of major depressive disorder relapse and recurrence with second- generation antidepressants. Psychiatric Services 59, 1121–1130.
Hardy M, Coulter I, Morton SC et al. (2002). S-adenosyl-methionine for treatment of depression, osteoarthritis, and liver disease (publication number, 02-E04). Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services.
Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews 61, 105–123.
Holtzheimer 3rd PE, Meeks TW, Kelley ME et al. (2008). A double blind, placebo- controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International Journal of Geriatric Psychiatry 23, 625–631.
Iosifescu DV, Nierenberg AA, Mischoulon D et al. (2005). An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 66, 1038–1042.
Judd L, Akiskal HS, Maser JD et al. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Journal of Affective Disorders 50, 97–108.
Keller MB, Lavori PW, Lewis CE, Klerman GL (1983). Predictors of relapse in major depressive disorder. Journal of the American Medical Association 250, 3299–3304.
Kennedy N, Paykel ES (2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135–144.
Kennedy SH, Rizvi S, Fulton K, Rasmussen J (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlaf axine XR. Journal of Clinical Psychopharmacology 28, 329–333.
Kessler RC, Berglund P, Demler O et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095–3105.
Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 40–45.
Kirsch I, Deacon BJ, Huedo-Medina TB et al. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine/Public Library of Science 5, e45.
Lauterbach E, Felber W, Muller-Oerlinghausen B et al. (2008). Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatrica Scandinavica 118, 469–479.
Leon AC (2007). The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. American Journal of Psychiatry 164, 1786–1789.
Leon AC, Solomon DA, Mueller TI et al. (2003). A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. American Journal of Psychiatry 160, 727–733.
Maj M, Veltro F, Pirozzi R et al. (1992). Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. American Journal of Psychiatry 149, 795–800.
McGrath PJ, Khan AY, Trivedi MH et al. (2008). Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. Journal of Clinical Psychiatry 69, 1847–1855.
McGrath PJ, Stewart JW, Fava M et al. (2006). Tranylcypromine vs. venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. American Journal of Psychiatry 163, 1531–1541.
McMahon FJ, Buervenich S, Charney D et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804–814.
Montejo AL, Prieto N, Terleira A et al. (2010). Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology 24, 111–120.
Mueller TI, Leon AC, Keller MB et al. (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. American Journal of Psychiatry 156, 1000–1006.
Mulder RT, Joyce PR, Frampton CM et al. (2008). Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatrica Scandinavica 118, 116–122.
Nakagawa A, Grunebaum MF, Ellis SP et al. (2007). Association of suicide and antidepressant prescription rates in Japan, 1999–2003. Journal of Clinical Psychiatry 68, 908–916.
Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 166, 980–991.
Nierenberg AA, Amsterdam JD (1990). Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry 51 (Suppl.), 39–47.
Nierenberg AA, Farabaugh AH, Alpert JE et al. (2000). Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157, 1423–1428.
Nierenberg AA, Husain MM, Trivedi MH et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine 40, 41–50.
Nierenberg AA, Papakostas GI, Petersen T et al. (2003). Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. Journal of Clinical Psychopharmacology 23, 92–95.
Papakostas GI (2009). The role of S-adenosyl methionine in the treatment of depression. Journal of Clinical Psychiatry 70 (Suppl. 5), 18–22.
Papakostas GI, Homberger CH, Fava M (2008). A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of Psychopharmacology 22, 843–848.
Papakostas GI, Mischoulon D, Shyu I et al. (2010). S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. American Journal of Psychiatry 167, 942–948.
Papakostas GI, Perlis RH, Scalia MJ et al. (2006). A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 26, 56–60.
Papakostas GI, Peterson T, Sklarsky KG et al. (2007 b). Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research 149, 195–200.
Papakostas GI, Thase ME, Fava M et al. (2007 a). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62, 1217–1227.
Perlis RH, Moorjani P, Fagerness J et al. (2008). Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK 1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33, 2810–2819.
Perlis RH, Patrick A, Smoller JW, Wang PS (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34, 2227–2236.
Pintor L, Gasto C, Navarro V et al. (2003). Relapse of major depression after complete and partial remission during a 2-year follow-up. Journal of Affective Disorders 73, 237–244.
Posternak M, Novak S, Stern R et al. (2008). A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International Journal of Neuropsychopharmacology 11, 15–25.
Rasmussen NA, Schroder P, Olsen LR et al. (2005). Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptoms Checklist (SCL-92). Nordic Journal of Psychiatry 59, 173–178.
Roy-Byrne P, Post RM, Uhde TW et al. (1985). The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica (Suppl.) 7, 3–34.
Ruhe HG, Huyser J, Swinkels JA, Schene AH (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry 67, 1836–1855.
Rush AJ, Trivedi MH, Wisniewski SR et al. (2006 a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905–1917.
Rush AJ, Trivedi MH, Wisniewski SR et al. (2006 b). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 1231–1242.
Rush AJ, Wisniewski SR, Warden D et al. (2008). Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Archives of General Psychiatry 65, 870–880.
Sanacora G (2009). Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. Journal of Clinical Psychiatry 70, 1473–1474.
Schindler F, Anghelescu IG (2007). Lithium vs. lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 22, 179–182.
Serretti A, Kato M, De Ronchi D, Kinoshita T (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 12, 247–257.
Simpson HB, Nee JC, Endicott J (1997). First-episode major depression: few sex differences in course. Archives of General Psychiatry 54, 633–639.
Solomon DA, Keller MB, Leon AC et al. (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry 157, 229–233.
Stahl SM, Fava M, Trivedi MH et al. (2010). Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 71, 616–626.
Trivedi MH, Fava M, Wisniewski SR, Thase ME (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 1243–1252.
Uher R, Huezo-Diaz P, Perroud N et al. (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 4, 225–233.
Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ (2005). Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19, 137–146.
Wade AG, Schlaepfer TE, Andersen HF, Kilts CD (2009). Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43, 568–575.
Weihs KL, Houser T, Batey SR et al. (2002). Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biological Psychiatry 51, 753–761.
Wilson K, Mottram P, Sivanranthan A, Nightingale A (2003). Antidepressants vs. placebo for the depressed elderly. Cochrane Database of Systematic Reviews 2, CD000561.
Zajecka J, Schatzberg A, Stahl S et al. (2010). Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 30, 135–144.
Zarate CA Jr, Singh JB, Carlson PJ et al. (2006 a). A randomized trial of an N-methyl-D- aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856–864.
Zarate CA, Singh JB, Quiroz JA et al. (2006 b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 163, 153–155.
Zimmerman M, Posternak MA, Chelminski I (2002). Symptom severity and exclusion from antidepressant efficacy trials. Journal of Clinical Psychopharmacology 22, 610–614.